Response to Letters Regarding Article, "Sudden Cardiac Arrest and Death Following Application of Shocks From a TASER Electronic Control Device"
Douglas P. Zipes

_Circulation._ 2013;127:e261-e262
doi: 10.1161/CIRCULATIONAHA.112.147520
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/127/1/e261

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/
Response to Letters Regarding Article, “Sudden Cardiac Arrest and Death Following Application of Shocks From a TASER Electronic Control Device”

I thank the authors of the Letters to the Editor for their interest in my article. As Drs Nanthakumar and Waxman indicate, the left ventricular epicardium becomes inexcitable during ischemia (such as would be provoked by ventricular fibrillation [VF]), whereas Purkinje fibers and endocardial muscle remain fully responsive.1 In fact, one can record asystole in some ECG leads when VF is actually still present in others.2 I agree that determining the response to a TASER shock that induces rapid capture and VF is critical. I am glad they think the article sheds light on a complicated issue.

Drs Vilke, Chan, and Karch question the “clinically healthy” wording I explained in a published correction for my article3 to mean clinically healthy from a cardiovascular standpoint without manifest cardiovascular symptoms. They suggest that several people may have had cardiac pathology. If true, underlying heart disease or substances such as alcohol and some drugs would likely facilitate electrical induction of VF from the TASER shock. If the pathology were the cause of the VF, one would have to assume it triggered VF precisely at the time of the TASER shock, an improbable coincidence. They indicate that one case had long QT “on the day of his TASER activation.” This was present in the ECG recorded in the postresuscitation period after termination of VF with shocks of 200, 300, and 360 joules; infusion of drugs including epinephrine and lidocaine; a blood alcohol level of 0.35 g/100 mL; serum potassium of 3.3 mEq/L; and severe cerebral hypoxia. After cardiac recovery, the QT returned to normal. They indicate that another case subject had probe and drive stun shock applications, which is correct. In this individual, sufficient electricity delivered via 13 shocks in one or both modes of shock administration totaling 62 seconds reached his heart to cause cardiac arrest.

The authors state that swine hearts fibrillate more easily than humans but cite no supporting evidence. Swine studies have been published totaling 62 seconds reached his heart to cause cardiac arrest. Untreated VF evolves to fine VF and asystole over time.

In my opinion, TASER ECD safety has not been adequately demonstrated. In fact, the animal studies and clinical reports discussed in my article elevate and focus on the issue of safety, not reduce it. However, my aim is not whether the use of TASER International’s products is appropriate; that is a decision for law enforcement experts. My goal is to educate users about the potential for cardiac arrest: (1) treat the ECD with the same respect as a firearm; (2) avoid chest shots and long and repeated trigger pulls if possible; (3) suspect cardiac arrest in any unresponsive individual, regardless of apparent movement or perception of a pulse or respiration; and (4) call for medical support and apply cardiopulmonary resuscitation and an automated external defibrillator as soon as possible.

Drs Heegaard et al suggest possible bias in my interpretation of facts in several of the cases. I respectfully disagree and suggest that Drs Heegaard et al could be biased because they own TASER shares (Dr Heegaard), serve on the TASER Scientific Medical Advisory Board, and function as an expert witness on behalf of TASER, International (Dr Luceri), as they have acknowledged.

In that regard, the 3 letters of criticisms were sent by physicians with TASER relationships and were directed toward aspects of a few single cases, not against the overall concept of TASER-induced VF. In my opinion, to a reasonable degree of medical certainty, the published body of evidence now makes it perfectly clear that a TASER X26 ECD shock can induce VF in humans, transforming the argument from if it can happen to how often it happens.

Disclosures

Dr Zipes is an expert plaintiff witness against TASER, International, Inc.

Douglas P. Zipes, MD
Indiana University School of Medicine
Indianapolis, IN

References


